Behandelt werden unter anderem Migrne, Polyneuropathie, Parkinson, Multiple Sklerose, Epilepsie und Demenzerkrankungen
The current medications vary in mechanism and magnitude: Semaglutide (Ozempic) targets GLP-1 receptors - around 15% average weight loss Tirzepatide (Mounjaro) targets GLP-1 + GIP - around 20% weight loss, often better GI tolerance Retatrutide (Phase 3 Trials) targets three receptors around 24% weight loss in trials, with broader metabolic effects The real risk is muscle mass loss
GLP-1 Studio Podcast Honest conversations with relatable patient stories, expert insights that wont make your eyes glaze over, and advocacy for affordable access
Diabetes Care 43 , 23032312 (2020)
improved liver function," Korner said, "that's, to me, the exciting part." The-CNN-Wire & 2025 Cable News Network, Inc., a Warner Bros
A compound that perturbs the TCA cycle suggests mitochondrial targeting